Study:
A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer`s Disease
Rationale:
n/a
Purpose:
Retinoid X receptors (RXR) are nuclear receptors that have been linked to numerous metabolic
pathways relevant to Alzheimer`s disease (AD) and Aß (harmful protein) production and
removal. The study drug "bexarotene" is an FDA approved anti-cancer agent but is not
approved for use in Alzheimer`s disease. Bexarotene acts as an RXR agonist that has reduced
Aß (harmful protein) in the brain in experimental models of Alzheimer`s disease.
This study aims to determine the safety and effect on abnormal proteins found in the brain
(based on brain scans) of 300 mg of "bexarotene" administered for one month compared to
placebo (inactive agent).
Study Status: Not yet recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Alzheimer`s Disease |
Drug: Bexarotene
Drug: Placebo |
Phase 2 |
Verified by
The Cleveland Clinic
February, 2013
Sponsored by: The Cleveland Clinic
Information provided by: The Cleveland Clinic
ClinicalTrials.gov identifier: NCT01782742
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada 89106
United States
Jeffrey L Cummings, MD, ScD., Principal Investigator